Examination of combination and maintenance therapy with Adapalene Gel 0.1% for acne vulgaris

Examination of combination and maintenance therapy with Adapalene Gel 0.1% for acne vulgaris - Examination of combination and maintenance therapy with Adapalene Gel 0.1% for acne vulgaris

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004442

Enrollment

350

Registered

2010-10-26

Start date

2010-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne vulgaris

Interventions

(Study-1)Group A:Nadifloxacin will be applied for 12 weeks. (Study-1)Group B:Adapalene gel 0.1% and Nadifloxacin will be applied for 12 weeks. (Study-1)Group C:Adapalene gel 0.1% and Roxithromycin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who has inflammatory lesion 2)Patients who agreeded with their written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients taking some medications (orally,topically, or injective agents, or chemical treatments) expected to be effective to acne vulgaris within one month before the registration of this research. 2) Patients with hypersensitivity to any of the study drugs 3) Patients continuously receiving non-steroidal anti-inflammatory drugs(ibuprofen,etc) 4) Women who are pregnant,might be pregnant or lactating or planning a pregnancy 5) Patients who are considered to be unsuitable for this study by the investigator

Design outcomes

Primary

Measure	Time frame
(Study-1)Percent reduction in total lesion (inflammatory lesion + comedone) counts of acne vulgaris on the face(inflammatory lesion + comedone) (Study-2)Period until increasing of inflammatory lesion	—

Secondary

Measure	Time frame
Change in QOL Overall clinical evaluation(after study1) *Safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026